tirzepatide approval obesity Tirzepatide: First | Drugs GLP-1 medications are marketed to

Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995), including statements about the supply and access of Zepbound (tirzepatide) as a treatment for adults with obesity or overweight and reflects Lilly's current belief and expectations

The math still works

Because it activates two metabolic hormone pathways, it may provide greater appetite regulation for some individuals

One trial showed participants taking 7.2mg weekly losing on average 18.7%, with many reaching 20-25% weight loss thresholds

Can Mounjaro be used without diabetes